|Title:||Pharmaceutical combination for use in glycemic control in diabetes type 2 patients|
|Abstract:|| The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.|
|Inventor(s):|| Niemoeller; Elisabeth (Frankfurt am Main, DE), Muehlen-Bartmer; Isabel (Frankfurt am Main, DE), Silvestre; Louise (Paris, FR), Boka; Gabor (Paris, FR), Miossec; Patrick (Paris, FR) |
|Assignee:|| Sanofi-Aventis Deutschland GMBH (Frankfurt am Main, DE) |
1. A method for improvement of glycemic control in a patient having diabetes type 2, comprising administering to the patient a therapeutically effective amount of the
pharmaceutical combination comprising: (a) desPro.sup.36Exendin-4(1-39)-Lys.sub.6-NH.sub.2 and/or a pharmaceutically acceptable salt thereof, and (b) a glitazone and/or a pharmaceutically acceptable salt thereof; and wherein the patient has a
haemoglobin A1c (HbA.sub.1c) value of at least 8% and a fasting plasma glucose of at least 9 mmol/L when treated with glitazone alone.
2. The method of claim 1, wherein the patient is an adult.